SCHEMBL4464087

SCHEMBL4464087

COc1c(C(C)(C)C)cc(-c2cccc(Br)n2)cc1C(C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 4/20 0.43
ADORA2A P29274 1/20 0.41
ADORA1 P30542 1/20 0.41
PTGS1 P23219 1/20 0.40
HDAC8 Q9BY41 2/20 0.36
TNFRSF1A P19438 2/20 0.35
BRD4 O60885 1/20 0.35
DHFR P00374 1/20 0.35
EGFR P00533 1/20 0.34
ERBB2 P04626 1/20 0.34
ADRA2A P08913 1/20 0.34
ADRA2C P18825 1/20 0.34
ADRA1D P25100 1/20 0.34
ADRA1A P35348 1/20 0.34
ADRA1B P35368 1/20 0.34
MEN1 O00255 1/20 0.33
MAPT P10636 1/20 0.33
TSHR P16473 1/20 0.33
KMT2A Q03164 1/20 0.33
ATM Q13315 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17144925 0.80 BRD4 (0.54) HDAC8BRD4MEN1MAPTTSHR
SCHEMBL30112724 0.76 PTGS2 (0.43) PTGS2ADORA2AADORA1PTGS1TNFRSF1A
SCHEMBL28959881 0.76 PTGS2 (0.43) PTGS2ADORA2AADORA1PTGS1TNFRSF1A
SCHEMBL13959332 0.76 PIM1 (0.41) PTGS2ADORA2AADORA1PTGS1MEN1
SCHEMBL4455081 0.76 KDM4E (0.41) MEN1MAPTKMT2A
SCHEMBL28959885 0.75 PTGS2 (0.42) PTGS2ADORA2AADORA1PTGS1TNFRSF1A
SCHEMBL28959866 0.75 PTGS2 (0.39) PTGS2ADORA2AADORA1PTGS1TNFRSF1A
SCHEMBL30112512 0.75 PTGS2 (0.39) PTGS2ADORA2AADORA1PTGS1TNFRSF1A
SCHEMBL28959870 0.72 PTGS2 (0.39) PTGS2ADORA2AADORA1PTGS1TNFRSF1A
SCHEMBL30112505 0.72 PTGS2 (0.39) PTGS2ADORA2AADORA1PTGS1TNFRSF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090030012-A1 Pyridine, Pyrimidine and Pyrazine Derivatives as Cxcr3 Receptor Modulators MERCK SHARP & DOHME CORP. 2009-01-29 US disclosed
US-20090030012-A1 Pyridine, Pyrimidine and Pyrazine Derivatives as Cxcr3 Receptor Modulators MERCK SHARP & DOHME CORP. 2009-01-29 US disclosed
US-20090030012-A1 Pyridine, Pyrimidine and Pyrazine Derivatives as Cxcr3 Receptor Modulators MERCK SHARP & DOHME CORP. 2009-01-29 US disclosed
WO-2007100610-A2 PYRIDINE, PYRIMIDINE AND PYRAZINE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS MERCK & CO., INC. (US) 2007-09-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030012-A1 Pyridine, Pyrimidine and Pyrazine Derivatives as Cxcr3 Receptor Modulators CXCR3, CXCR1, CXCR5 PTGS2 572/4885ADORA2A 42/4885ADORA1 67/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.